Mesoblast fuses Phase II

By Kate McDonald
Tuesday, 28 April, 2009

Melbourne’s Mesoblast has received approval to being a Phase II trial of its allogeneic stem cell product NeoFuse in cervical spine fusion.

The trial, to be held at Melbourne’s Epworth Hospital, will compare NeoFuse with autograft. Twenty-four patients with irreversible, end-stage degenerative disc disease will take part in the randomised, controlled trial.

Mesoblast is also working on lumbar spinal fusion and on repair or regeneration of discs in patients with earlier stage disease.

Related News

Less penicillin needed to treat Strep A infection than we thought

It's never been known exactly how much penicillin prevents sore throats — the most...

Stress disrupts emotion control in mental illness

Acute stress may impair key brain functions involved in managing emotions — particularly in...

Organoid platform enables closer study of bat-borne viruses

Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd